diabetestalk.net

Indian Insulin Market Size

Human Insulin Market - Drugs (biologics, Biosimilars), Type (short Acting, Long Acting, Premixed), Brands (lantus, Novorapid, Humalog), Delivery Devices (pens, Pen Needles, Syringes), Applications (type 1 Diabetes, Type 2 Diabetes) - Forecasts To 2020

Human Insulin Market - Drugs (biologics, Biosimilars), Type (short Acting, Long Acting, Premixed), Brands (lantus, Novorapid, Humalog), Delivery Devices (pens, Pen Needles, Syringes), Applications (type 1 Diabetes, Type 2 Diabetes) - Forecasts To 2020

HOME › Top Market Reports › Human Insulin Market - Drugs (Biologics, Biosimilars), Type (Short Acting, Long Acting, Premixed), Brands (Lantus, NovoRapid, Humalog), Delivery Devices (Pens, Pen Needles, Syringes), Applications (Type 1 Diabetes, Type 2 Diabetes) - Forecasts to 2020 The global human insulin market is projected to reach USD 39.13 Billion by 2020 growing at a CAGR of 8.1% from 2015 to 2020. Base year considered for the report is 2014. Objectives of the study are: To define, describe, and forecast the global human insulin market on the basis of product, human insulin drugs type, human insulin drugs brand, delivery device, and application To provide detailed information regarding major factors influencing growth of the market (drivers, restraints, opportunities, and challenges) To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for leading market players To forecast the size of the market segments with respect to four main regions, namely, North America (U.S. and Canada), Europe (Germany, France, U.K., and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and the Rest of the World To strategically profile the key market players and comprehensively analyze their market shares and core competencies2 To track and analyze competitive developments such as joint ventures; mergers and acquisitions; new product developments; and partnerships, agreements, and collaborations in the human insulin market Research Methodology This research study involved the extensive use of secondary sources, directories, and databases (such as Hoovers, Bloomberg Busi Continue reading >>

Ims Health Market Reflection Report For June 2016

Ims Health Market Reflection Report For June 2016

Every month, MedicinMan in partnership with IMS Health, brings our readers the latest industry numbers related to sales and revenues of the top companies, brands and therapy areas in the Indian Pharmaceutical Market. The Indian Pharmaceutical Market (IPM) was valued at Rs. 9162 crores in the month of June 2016 clocking a 9.6% growth over same period last year (SPLY). This is seen revival on track after a dip in growth observed in earlier months of 2016 post the ban imposed on 344 FDCs by the Government of India which affected the buying patterns in the market. On a MAT June basis, the industry was valued at Rs. 107,019 crores and reflected a 13% growth. The retail channel is the largest channel in IPM contributing 84% of the overall sales and reflects a 9% growth. The hospital and doctor channel contributed to 16% of the overall sales and reflected a growth of 17% on a MAT June basis. It is expected that the hospital channel will continue to report robust growth rates due to rapid capacity expansion in this space. The retail channel is the largest channel in IPM contributing 84% of the overall sales and reflects a 9% growth. The hospital and doctor channel contributed to 16% of the overall sales and reflected a growth of 17% on a MAT June basis. It is expected that the hospital channel will continue to report robust growth rates due to rapid capacity expansion in this space. IPM has witnessed some big ticket M&As over the past few years. Despite this consolidation, the industry remains fragmented with top 10 players contributing 43% of overall sales and reflecting a robust 11% growth for the month of June 2016. Companies ranked 11-20 contributed 21% of total revenues for the month reflecting a growth of 10% aided by strong growth posted by Wockhardt (23%), Glenmark (19% Continue reading >>

Lupin Launches Insulin Glargine In India

Lupin Launches Insulin Glargine In India

Indian pharma company, Lupin Limited announced a strategic distribution agreement with LG Life Sciences of South Korea to launch Insulin Glargine, a novel insulin analogue under the brand name Basugine™. According to the agreement, Lupin would be responsible for marketing and sales of Basugine™ in India. The overall diabetes market size within the Indian pharmaceutical market stood at Rs. 6032 Crore growing at 18% (IMS MAT April 2014). The total insulin analogue market size is valued at Rs. 585 Crore with 3 year CAGR of 24%. The total glargine molecule market is Rs. 218.5 Crore with 3 year CAGR of 23%. Lupin ranks 2nd in the conventional insulin market and grew more than the market at 10.82% in April 2014 (IMSD MAT), while the market grew at 8%. Lupin is amongst the fastest growing players in the Oral Anti-Diabetes Drugs market and also in the insulin segment. Insulin Glargine is indicated for once – daily subcutaneous administration for the treatment of adult patients with type 1 diabetes mellitus or in type 2 diabetes mellitus; patients who need basal insulin (long acting) for controlling hyperglycemia. The primary activity of insulin, including Insulin Glargine, is the regulation of glucose metabolism. Insulin and its analogues lower blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Announcing the launch, Mr. Shakti Chakraborty, Group President, India Region Formulations, Lupin said– “I believe that our entry into the insulin analogue market with launch of Basugine is a step in the right direction. Lupin’s foray in this segment will help us furtherstrengthen our Diabetes portfolio enabling us to grow deeperinto the Diabetes segment and will fuel our growth in Continue reading >>

Statistics And Market Analysis Of Insulin Market In India - Powerpoint Ppt Presentation

Statistics And Market Analysis Of Insulin Market In India - Powerpoint Ppt Presentation

Global Diabetes Disposable Insulin Pen Market Report: Country Outlook, Analysis, Size, Share and Forecast 2017 – 2022 - DPI Research published a latest report titled"Global Diabetes Disposable Insulin Pen Market Report: Country Outlook, Analysis, Size, Share and Forecast 2017 – 2022" to its databases Buy Now: Diabetes Disposable Insulin Pen Market is likely to reach more than US$ 9Billion across the ten major markets (10MM) of the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China, India and Brazil by the year end of 2022. Market growth can be attributed to factors such as growing diabetes patient population, high adoption rate, user–friendly design, rising popularity among consumers, help avoid over/under–dosing of insulin, rising market demand for human insulin analogs, government support and technological advancements in the field of insulin pen devices. | PowerPoint PPT presentation | free to view Continue reading >>

Diabetes Therapeutics Market In India To 2018 - Rapid Uptake Of Dpp-iv Inhibitors, Glp-1 Agonists And Expanding Insulin Segment To Drive Growth

Diabetes Therapeutics Market In India To 2018 - Rapid Uptake Of Dpp-iv Inhibitors, Glp-1 Agonists And Expanding Insulin Segment To Drive Growth

Description GBI Research, the leading business intelligence provider, has released its latest research “Diabetes Therapeutics Market in India to 2018 - Rapid Uptake of DPP-IV Inhibitors, GLP-1 Agonists and Expanding Insulin Segment to Drive Growth”, which provides insights into the India anti-diabetes market until 2018. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. Insights into the diabetes epidemiology, cost of therapy, research and development pipeline and the promising molecules which are anticipated to be launched by 2018 are discussed in the report. The report provides an in-depth analysis type 1 and type 2 diabetes. The report provides an in-depth analysis on oral anti-diabetics agents, insulin products and drivers and barriers that could significantly impact the overall anti-diabetes market during the forecast period. Additionally, it explores the competitive landscape, including benchmarking the top companies in the market and the key issues and trends that are likely to have an impact on the Indian diabetes market during the forecast period. Finally, a key trend analysis for mergers and acquisitions and licensing agreements involving diabetes therapies is also discussed in the report. GBI Research’s analysis revealed that the overall anti-diabetes market in India was worth $680.3m in 2011 and is projected to grow at a CAGR of 11.3% between 2011 and 2018 to reach $1,446m in 2018. High and growing diabetes population in the country, rising obese and geriatric population, and rapid market adoption of drugs from the classes such as Dipeptidyl Peptidase 4 (DPP-4) inhibitors, Glucagon-Like Peptide (GLP)-1, Sodium-Glucose Trans Continue reading >>

Lupin And Eli Lilly Expand Partnership In India

Lupin And Eli Lilly Expand Partnership In India

HOME > MEDIA > PRESS RELEASES Lupin to market Lilly’s rapid-acting Insulin analog Lispro under the brand name Eglucent® According to the agreement, Lupin will market and sell Eglucent® through its own specialty field force while Lilly will be responsible for manufacturing and import. Lilly will continue to sell Lispro under the brand name Humalog® through its existing channels. Lupin had earlier collaborated with Lilly (July, 2011) to promote and distribute Lilly’s Huminsulin range of products in India and Nepal. Eglucent® is indicated for the treatment of patients with diabetes mellitus. It is an injectable medication designed to improve blood sugar control in patients with type 1 and 2 diabetes. Eglucent® will be available in the Indian market in both, the cartridge and disposable pen form. Eglucent® is a prescription drug that should be taken only when prescribed by a registered physician. It is intended as an adjunct to diet and exercise to improve the glycemic control. Lupin is the 5th largest company in the Anti-Diabetes segment with a market share of 6.34% growing at 18% (IMS MAT September 2016). Lupin also has the distinction of being the only company in the Anti-Diabetes market with a contemporary portfolio comprising of oral anti-diabetes drugs (OAD) and injectable drugs like conventional and analog insulins. Lupin’s anti-diabetic portfolio contributes 16% to its India formulations sales (FY 2016). The Indian diabetes market is valued at INR 9,272 crore and is growing at 19% (IMS MAT September 2016). The total insulin market is valued at INR 2,207 crore, out of which the insulin analogue market size is valued at INR 1,106 crore with a 3 year CAGR of 28% (IMS MAT September 2016). The total insulin Lispro molecule market size is INR 142 crore with a Continue reading >>

Insulin Market All Set To Reach $47.54 Billion By 2020: New Report By Grand View Research, Inc.

Insulin Market All Set To Reach $47.54 Billion By 2020: New Report By Grand View Research, Inc.

San Francisco, California, July 15, 2015 (GLOBE NEWSWIRE) -- The global market for insulin is expected to reach USD 47.54 billion by 2020, according to a new study by Grand View Research, Inc. Growing global prevalence of type I and type II diabetes and the presence of high unmet needs in emerging markets such as India and China are expected to be two of the most significant growth drivers of this market. Moreover, increasing incidence rates of lifestyle induced diseases such as obesity and growing global geriatric population base are expected to serve the global insulin market as drivers. The global intermediate and long acting insulin segments were two of the largest markets in 2013 and together accounted for over 45% of the overall revenue. Higher efficacy exhibited by these segments in terms of insulin peak time is one of the major factors accounting for their large market shares. Browse to access In-depth research report on Global Insulin Market with detailed charts and figures: Further key findings from the study suggest: Insulin analogs were the most dominant source in 2013 and accounted for over 70% of the revenue. These products are rapidly substituting the human recombinant insulin products by exhibiting higher efficacy. North America was the largest regional market in 2013, accounting for over 40% of global revenue. The presence of sophisticated healthcare infrastructure, high type I diabetes prevalence and patient disposable incomes in this region are some of the factors expected to drive market growth. Emerging markets including Asia Pacific accounted for 26.5% of global revenue in 2013. Asia Pacific insulin market is expected to grow at the highest CAGR of over 15% from 2014 to 2020 on account of the presence of high unmet medical needs pertaining to diabe Continue reading >>

Idc Designs Insulin Pens For Indian Market

Idc Designs Insulin Pens For Indian Market

Award winning product designer, Industrial Design Consultancy Ltd (IDC), has just completed a project to develop both disposable and reusable insulin pens for Indian consumers. The resulting products are expected to dramatically advance diabetes treatment in India, by offering a portable, discreet, quick and easy insulin dosage system for users on the move. Indian company, Wockhardt, was keen to introduce affordable disposable and reusable insulin pens to Indian healthcare but the patent restrictions on existing designs were such that they were unable to cost-effectively go into production. In order to overcome this, Wockhardt contracted IDC to design a completely new insulin pen, which would give class-leading functionality and avoid all the existing patents. Virtually all elements of the conventional insulin pens were patented, so IDC was challenged to find successful design alternatives, which also resulted in an improved product. It was important that the insulin pens were designed to be compact and discreet, with an easy dosing facility for people with vision or dexterity problems. IDC’s in-house engineers worked closely with its product designers to ensure that use-ability was a key priority. The pens are manufactured entirely from plastic and the internal mechanisms developed give an audible and sensory click when setting and delivering a dose. They also allow dose resetting without wasting medicine, and the reusable product features a magnifying dose window. The final insulin pen design was the size of a marker pen. Wockhardt’s reusable insulin pen contains a cartridge of insulin, which provides enough insulin to last for several days. The cartridge is simply replaced when it becomes empty – this reusable pen could be used for several years with good care. Continue reading >>

The Market Size Of India Insulin Market In Terms Of Revenue

The Market Size Of India Insulin Market In Terms Of Revenue

The industry research publication titled ‘India Insulin Market Review to 2018 - Intensifying Strategic Alliances Between Companies’ presents a comprehensive analysis of market size by value of major types (human insulin, analog insulin, premix, rapid acting, long acting) of insulin consumed in India. The report entails the segment wise market share analysis and company profiles of major players in the insulin market in India. The future prospects and opportunities in the market have also been discussed in the report. The economic advancement of any country is paradoxical in nature. While on one hand it increases the affluence of the masses, the other side is characterized by diseases that are accompanied by passive lifestyles. From the several diseases caused by a sedentary form of life such as cardiovascular ailments, hypertension and high blood pressure, diabetes is also increasing at an alarming rate, especially in the developing countries. India was resident to nearly 61.5 million people suffering from diabetes in 2013, which is the second largest in the world after China. The prevalence of diabetes has made it the fifth largest disease in India. Diabetes in India is reaching epidemic proportions. Rapid cultural changes such as increasing urbanization, modified diet patterns and sedentary lifestyles among the young generation, have heightened the prevalence of diabetes in India. In 2013, while 61.5 million people suffered from diabetes in the country, another 30 million were in the pre-diabetes group. Medication for the diabetic population is the need of the hour since the disease is adding significantly to the mortality rate of India. In FY’2008, the revenue generated by the sales of insulin in India was estimated to be USD ~ million and reached USD ~ million Continue reading >>

Lupin To Market Eli Lilly's Insulin Analog Product In India

Lupin To Market Eli Lilly's Insulin Analog Product In India

Lupin and Eli Lilly have expanded partnership in India with the Mumbai-based pharma company launching diabetes drug Eglucent, a new brand of Lilly’s rapid-acting insulin analog Lispro, in the country. As per the agreement, Lupin will market and sell Eglucent through its own specialty field force while Eli Lilly will be responsible for manufacturing and import. Lilly will continue to sell Lispro under the brand name Humalog through its existing channels. Lupin had earlier collaborated with Lilly (July 2011) to promote and distribute Lilly’s Huminsulin range of products ... MORE ON MARKETS: Quick Links Continue reading >>

India Is Home To Largest 'diabetes' Drugs Market Worldwide

India Is Home To Largest 'diabetes' Drugs Market Worldwide

Diabetes has been termed the 'Mother of all Diseases' and sadly despite of tremendous research by the medical industry, a permanent solution for it is yet to be found The Diabetes drug market is soon estimated to reach $55.3 billion by 2017 with foreign drum makers eyeing at India's growing diabetic population. Time to take a deep look at why drug companies are betting big on 'pharmerging' countries? PM Modi showed a lot of concern on the eve of International Yoga Day and urged yoga teachers to focus on reducing the number of diabetic patients in the India. It is time to contemplate his insistence over the issue and analyze the questions India is facing at the moment. With the world's largest population of diabetics, India is set to see the launch of a range of novel diabetes treatments from foreign drug makers such as Pfizer, Eli Lilly and Merck. Diabetes has been termed the 'Mother of all Diseases' and sadly despite of tremendous research by the medical industry, a permanent solution for it is yet to be found. Even the best medicines can only control diabetes for the time being while the dosage keeps increasing as time progresses. However, it is said the yoga can help maintaining almost all of the bodily functions at the optimum level and diabetes can be controlled by it as well. Many postures and breathing exercises in yoga have known to be inducing the pancreas to produce enough insulin and regulate the blood sugar. But drug companies have been pitching innovative delivery systems, convenience and touch technology, to expand their consumer base in large markets like India. Multinational pharmaceuticals are planning to capture a market of 32 million to 57.2 million people by 2025. Pfizer, GlaxoSmithKline, Merck, Eli Lilly, Novartis, AstraZeneca, Sanofi all wish to ha Continue reading >>

Biosimilar Insulin And Costs

Biosimilar Insulin And Costs

Biosimilars are approved copies of already marketed biological medicines. They provide an alternative to existing biological medicines that have lost their patent protection. The first biosimilar insulin (BioIns) will soon be launched on the EU market (Abasaglar, an insulin glargine developed by Eli Lilly and Boehringer Ingelheim). As the lawsuit with Sanofi has come to an end, this same insulin will be released on the US market soon but under a different name (Basaglar). Interestingly, this insulin was not approved following the new 351(k) biosimilar pathway (see below). It is of note that a major pharmaceutical player (and not a generics or specialty biotech company) has won the race to have the first BioIns approved. An Indian pharmaceutical company tried twice in the past to get approval in the EU, but failed both times.1 From the approval process seen with Abasaglar and the previous attempts to get an insulin approved in the EU, this is not an easy task. However, it can be expected that more BioIns will come to the markets over the next years, that is, a number of different insulin glargines, but also BioIns of rapid-acting insulin analogs. Nevertheless, it is of note that a large pharmaceutical company like Pfizer has stepped back from codeveloping a BioIns with an Indian company after being in cooperation with them for a while. As with the reduction in price seen when biosimilars of other drugs outside diabetes care came to the market, the expectation is that the market introduction of these BioIns will also have an impact on the price of insulin. The question is, will insulin costs decline in the next years to a similar extent as with other biosimilars or even to an extent as was observed with generic drugs? Or in other words, what savings are to be expected wit Continue reading >>

Yearly Spend On Diabetes Is Rs 1.5 Lakh Cr, Rising By 30% Pa

Yearly Spend On Diabetes Is Rs 1.5 Lakh Cr, Rising By 30% Pa

The annual spend on account of diabetes treatment in India is pegged at Rs 1.5 lakh crore, 4.7 times the Centre's allocation of Rs 32,000 crore on health and three-fourth of the budgeted service tax collections this fiscal, with experts saying that the cost of treatment of the disease is rising by 20-30% every year. A study by Lancet has ex pressed concern over the rising cost of insulin, making it virtually unaffordable for a large chunk of patients globally with India, known as the diabetes capital of the world, accounting for 60 million of them. The economic burden of diabetes is high in the country as most patients pay outof-pocket, and due to lack of medical reimbursement.While diabetes rate has increased by around 45% globally, it has jumped 123% in India between 1990 and 2013, according to the Institute for Health Metrics and Evaluation at the University of Washington. The cost of diabetes care, including direct as well as indirect costs as loss of production, was pegged at Rs 1.5 lakh crore in 2010 and has been rising significantly over the years. Pointing at rising costs, fewer generic developments, limited competition and huge mark-ups by phar maceutical companies in the insulin space, the Lancet study says, “Substantial attention has been given to the issue of access to medicines for communicable diseases; however, access to essential medicines for diabetes, especially insulin, has had insufficient focus.“ Highlighting the factors affecting affordability , the study says one possible explanation is the market domination by three multinational companies, which control 99% of the global insulin market in terms of value and 96% in terms of volume. Insulin is used by all people with Type 1 diabetes and up to a quarter of those with Type 2 disease to control b Continue reading >>

Indian Diabetes Market Report & Outlook For 2010-2015 Through Bharatbook.com

Indian Diabetes Market Report & Outlook For 2010-2015 Through Bharatbook.com

Bharatbook.com announces inclusion of latest report on "Indian Diabetes Market Report & Outlook For 2010-2015"(With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$ 424 Million. Although, this represents just a fraction of the global sales, IMARC expects this market to surge in the future. In 2009, Non-Insulin Anti-diabetics occupied 72% of the total diabetes market. Biguanides represented the leading drug class with a 43% market share. In the next five years, IMARC expects newer classes such as DPP-IV Inhibitors and GLP-1 Agonists to drive the Non-Insulin Anti-diabetics market. From a market share of 6% in 2009, IMARC expects DPP-IV Inhibitors to occupy 17% of the total Non-Insulin Anti-diabetics market by 2015. Unlike Non-Insulin’s, the Insulin market in India was concentrated with the top five players occupying 96% of the total market. The Insulin market is expected to grow at a CAGR of 25% between 2010 and 2015, registering sales worth US$448 Million. During the next five years, the main drivers of this market will be the growth in the total drug treated population coupled with a much improved access and administration of Insulin. Report Highlights * A growing drug treated population coupled with the launch of several new drugs will drive the Indian diabetes market to US$1.4 Billion by 2015. * In 2009, the market for Non-Insulin Anti-diabetics was worth US$ 306 Million. This represented a highly fragmented market with USV being the leading player with a 14% share. * USV’s Glycomet GP (Glimepiride+Metformin) was the leading drug in the Non-Insulin Anti-diabetics market with sales worth nearly US$ 10.5 Million * IMARC ex Continue reading >>

3. Biogenerics-need For Regulatory Development In India

3. Biogenerics-need For Regulatory Development In India

Palleti Lakshmi Prathusha N. Vishal Gupta* Pharmaceutical Quality Assurance Group, Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Shri Shivarathreeshwara Nagar, Mysore-570015, Karnataka, India Corresponding Author: N. Vishal Gupta Dept. of Pharmaceutics, JSS College of Pharmacy, Shri Shivarathreeshwara Nagar, Mysore - 570 015, Karnataka, India; E-mail: [email protected] Date of Submission: 18-05-2013 Date of Acceptance: 29-05-2013 Conflict of Interest: NIL Source of Support: NONE Copyright: © 2013 N. Vishal Gupta et al, publisher and licensee IYPF. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. Related article at Pubmed, Scholar Google Visit for more related articles at International Journal of Drug Development and Research First-generation biopharmaceuticals have come off patent or lose marketing exclusivity. This has paved the way for the manufacture of generic biopharmaceuticals which are otherwise called as biogenerics. According to estimation, biologic drugs worth more than $80 billion in global sales will lose patent protection by the year 2015, presenting a major opportunity for biogenerics. Biologic-based drugs are expected to push the contract manufacturing industry for growth and development over the next few years. Already India is enjoying a significant growth in the biogenerics manufacturing sector. But some of the significant obstacles with respect to regulations and their compliance with other countries must be considered. The main aim of the article is to demonstrate an immediate need for regulatory development of biogenerics in India. Since the market size for biogenerics is highly appreciable and has breaked the barriers of historically restricted usa Continue reading >>

More in insulin